funding from the University of Basel, the University Hospital Basel, Novartis, and the government of Basel-Stadt (F), Shulsky Foundation, National Centre of Competence in Research Molecular Systems Engineering (University of Basel and ETH Zürich), Swiss National Science Foundation, Wellcome Trust, Boehringer Ingelheim Pharma GmbH & Co. KG; Gerson Lehrman Group, Guidepoint, Astellas Institute for Regenerative Medicine, Gensight Biologics, Intellia Therapeutics, Inc., Ionis Pharmaceuticals, Inc., ReNeuron Group Plc/Ora Inc; Genentech Inc./F. Hoffmann-La Roche Ltd, ReNeuron Group Plc/Ora Inc., Novo Nordisk (C)
Miller joined Pace five years ago, overseeing the firm's growth to a point where turnover reached £525m last year (Broadcast 9.7.01). However, in the last 12 months, turnover has tumbled by a third to £352m and profits have fallen from £38.1m to a loss of £29.5m (Broadcast 15.7.02). The firm's share price is now trailing along the floor at 14p compared with a high of around £4.25 at the start of the year.

According to finance director John Dyson, Miller's decision to quit did not come as a surprise. He said Miller had quit for personal reasons and that after being at the firm for five years, he wanted a change.

In a statement, the firm said it was now looking for a successor and that both internal and external